ImageneBio Inc
IMA
Company Profile
Business description
ImageneBio Inc is a clinical-stage biopharmaceutical company that develops differentiated therapies for immunological and inflammatory (I&I) diseases. The company is focused on developing IMG-007, a non-depleting anti-OX40 monoclonal antibody, for the treatment of atopic dermatitis.
Contact
12526 High Bluff Drive
Suite 345
San DiegoCA92130
USASector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
Stocks News & Analysis
stocks
Amazon earnings: Good results, with AWS still a winner; fear on profitability guidance is overblown
We think Amazon stock looks attractive.
stocks
Apple earnings: Strong iPhone beat brings our valuation up and tariff costs prove light for now
We think Apple stock looks fairly valued.
stocks
4 ASX shares that could be vulnerable to an August surprise
Any missteps this reporting season could be costly for these shares, which have all risen to lofty valuations.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,900.70 | 16.40 | -0.18% |
| CAC 40 | 7,546.16 | 225.81 | -2.91% |
| DAX 40 | 23,425.97 | 639.50 | -2.66% |
| Dow JONES (US) | 43,588.58 | 542.40 | -1.23% |
| FTSE 100 | 9,068.58 | 64.23 | -0.70% |
| HKSE | 24,507.81 | 265.52 | -1.07% |
| NASDAQ | 20,650.13 | 472.31 | -2.24% |
| Nikkei 225 | 39,949.12 | 850.48 | -2.08% |
| NZX 50 Index | 12,734.53 | 5.13 | 0.04% |
| S&P 500 | 6,238.01 | 101.38 | -1.60% |
| S&P/ASX 200 | 8,646.30 | 15.70 | -0.18% |
| SSE Composite Index | 3,559.95 | 13.26 | -0.37% |